HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)

This week, we're rerunning some popular posts while we prepare for tomorrow's live video webinar: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders. Click here to see the original post from April 2026. By Adam J. Fein, Ph.D.Drug Channels Institute's (DCI's) latest anal

By Drug Channels · Jun 11, 2026 · via Drug Channels

This is an aggregated industry headline. Read the full story at Drug Channels →

Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
The WeekFiercePharma ↗
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
Jun 12, 2026
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
The WeekFierceBiotech ↗
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, set…
Jun 12, 2026
J&J’s Imaavy Secures Trial Win, Eyes First Approval in Warm Autoimmune Hemolytic Anemia
The WeekBriefing
J&J’s Imaavy Secures Trial Win, Eyes First Approval in Warm Autoimmune Hemolytic Anemia
Johnson & Johnson reported pivotal trial success for Imaavy in warm autoimmune hemolytic anemia, a rare diseas…
Jun 12, 2026